Home / Recalls / Teva Pharmaceuticals USA, Inc / D-0357-2026

D-0357-2026 Class II Ongoing

Recalled by Teva Pharmaceuticals USA, Inc — Parsippany, NJ

Recall Details

Product Type
Drugs
Report Date
March 11, 2026
Initiation Date
January 29, 2026
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
19,056 bottles

Product Description

Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054, NDC: 45963-678-11

Reason for Recall

Failed Dissolution Specifications

Distribution Pattern

Nationwide

Code Information

Lot#: a) 0686H251, 0687H251, 10688H251, Exp.: 02/2027. .

Other recalls by Teva Pharmaceuticals USA, Inc

  • D-0354-2026 Class II — Metoprolol Succinate Extended-Release Tablets, 25 mg, 100 tablets bottles (NDC: (January 29, 2026)
  • D-0356-2026 Class II — Metoprolol Succinate Extended-Release Tablets, Rx Only, 100 mg, 100 tablets bott (January 29, 2026)
  • D-0355-2026 Class II — Metoprolol Succinate Extended-Release Tablets, 50 mg, 100 tablets bottles (NDC: (January 29, 2026)
  • D-0198-2026 Class III — Carton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose p (November 7, 2025)
  • D-0151-2026 Class II — Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg pe (October 13, 2025)
  • D-0106-2026 Class II — Prazosin Hydrochloride, Capsules, USP, 5 mg, Rx only, Distributed by TEVA PHARMA (October 7, 2025)
  • D-0104-2026 Class II — Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMA (October 7, 2025)
  • D-0105-2026 Class II — Prazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMA (October 7, 2025)
  • D-0473-2025 Class II — Metoclopramide Tablets, USP 10 mg, 100-count bottle, Rx only, Manufactured in Cr (May 23, 2025)
  • D-0218-2025 Class II — Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, (January 10, 2025)